Epidemiology

Your Organizational Guidance

ebpracticenet urges you to prioritize the following organizational guidance:

Opvolging en revalidatie van patiënten met aanhoudende klachten na COVID-19 in de eerste lijnPublished by: KU Leuven | Werkgroep Ontwikkeling Richtlijnen Eerste Lijn (Worel)Last published: 2023Suivi et revalidation des patients présentant des symptômes persistants après la COVID-19 en première lignePublished by: KU Leuven | Groupe de Travail Développement de recommmandations de première ligneLast published: 2023

Long COVID prevalence estimates vary widely owing to inconsistent definitions and heterogeneous methods of analysis.

In a systematic review and meta-analysis, approximately 63% of patients reported at least one symptom at 30 days after symptom onset/hospitalization, with 71% reporting at least one symptom after 60 days, and 46% at 90 days or more.[14] In another systematic review, 54% of patients reported at least one symptom at 1 month, 55% of patients reported at least one symptom at 2 to 5 months, and 54% of patients reported at least one symptom at 6 months or longer.[15] However, some studies report much lower rates of continuing symptoms after 12 weeks (2.3% to 3%).[16][17] A study that corrected for individual symptoms present before coronavirus disease 2019 (COVID-19) and the symptom dynamics in the population without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection found that 12.7% of patients are likely to experience long-term symptoms at 90 to 150 days after infection.[18] Persistent symptoms have been reported up to 12 months after discharge, but most people had a good and functional recovery during 1-year follow-up.[19][20] Persistent symptoms have also been reported at 2-year follow-up in a significant number of patients, with fatigue and muscle weakness being the most frequent.[21]

Prolonged illness can occur among young adults with no underlying comorbidities, and in patients who had mild disease.[22][23] Approximately 12% to 15% of patients who had mild symptoms still had symptoms up to 8 months later.[24] The number of symptoms at follow-up was associated with the symptom load during the acute phase of infection and the number of comorbidities in non-hospitalized patients.[25] Asymptomatic infection is associated with a lower risk of developing long-term sequelae.[26] Persistent symptoms have been reported in pregnant women and children. A meta-analysis found the prevalence was 25% in children and adolescents, with the most prevalent symptoms being mood symptoms, fatigue, and sleep disorders.[27] However, evidence in children is limited, heterogeneous, and based on low-quality studies.[28] Low-certainty evidence suggests that vaccination before SARS-CoV-2 infection may reduce the risk of long COVID. The impact of vaccination in people with existing long COVID is inconsistent.[29]

A meta-analysis of 54 studies and two medical record databases from 22 countries, which included data for 1.2 million individuals, estimated that 6.2% of people who had symptomatic COVID-19 experienced at least one of the following after 3 months: persistent fatigue with pain or mood swings (3.2%), cognitive problems (2.2%), or ongoing respiratory problems (3.7%).[10] This analysis did not include patients who were infected with the Omicron variant. The risk of developing long COVID may be lower among people infected with the Omicron variant compared with those infected with previous variants.[30][31]

Use of this content is subject to our disclaimer